Ben Chambers’ Post

We are thrilled for Rutgers research team Nervana Therapeutics to be part of the inaugural Venturium Virtual Showcase, where they will present the technology they developed at Rutgers to an audience of venture capital investors, venture studios, accelerators, incubators, industry partners, and entrepreneurs. Nervana Therapeutics' technology is a cellularized nerve regeneration graft (CNRG) that will speed patient recovery from peripheral nerve injury, improve recovery of sensation and motor function, reduce the need for extra surgeries, and decrease lifetime medical and socioeconomic costs of new and poorly-recovered injuries. Venturium 2024, co-sponsored by Rutgers Research, is a curated showcase highlighting spinouts and technologies from members of the Tech Transfer Venture Consortium (TTVC), including Rutgers and fellow co-sponsors Kentucky Commercialization Ventures, Innovate Carolina, Northeastern University Center for Research Innovation (CRI), and PCI Ventures. This event embodies a movement towards collaborative growth, technological advancement, and revolutionizing access to academic venture opportunities.   #RutgersInnovation #RutgersResearch #venturium24 #techtransfer #techinnovation #techventures #ventureforward #cofounderconnection #collaborativegrowth

👏 InterVene, Inc. raised $13 million in a Series A financing round to support its Recana catheter system. New investor Treo Ventures and existing investor RiverVest Venture Partners co-led the round. 🚀CEO Jeff Elkins commented: “RiverVest and Treo Ventures have strong track records in emerging endovascular fields and InterVene is thrilled to have their support as Recana reaches its final phases of development. We are excited to work with these seasoned, accomplished teams on such a significant opportunity to help physicians and their patients with venous conditions.” 🔗 Read more: https://lnkd.in/dYAq3JZA #MedicalDevice #MedTech #MedicalEquipment #HealthTech #SeriesA #MedicalDevices #Medicine #TechNews #Funding #MedTechFunding #FundingRound #AngelInvestment #GSCapitalConnect

ViaLase, Inc. , A clinical-stage #medical technology startup called has raised $40 million in a series C round of funding with the goal of filling gaps in the current paradigm for treating glaucoma. The financing was spearheaded by a new investor, with backing from existing investors such as Arboretum Ventures, Venture Investors, Health Fund, and Falcon Vision, an ophthalmology investment platform backed by KKR. The company, led by its founder and CEO, Tibor Juhasz, PhD, plans to use the money to make sure that the ViaLase® Laser* continues to advance clinically, legally, and #commercially. The first femtosecond laser used to treat primary open angle glaucoma (POAG) will be the ViaLase Laser, if approved. The ViaLuxeTM Laser System is intended to lower intraocular pressure (IOP) by non-invasively creating customised drainage channels via the #trabecular meshwork combining #femtosecond laser accuracy and micron-accurate gonio imaging. ViaLase, Inc Hadi Srass Ferenc Raksi Carlos Suarez Read more - https://lnkd.in/gBqtkjnF To share your startup story write us on - contact@startuprise.io #ViaLase #medicalstartup #medical #technology #glaucoma #commercially #accuracy #startup #startupnews #fundingnews #news

ShiraTronics Secures $66M to Advance Novel Therapy for Migraine MedTech startup ShiraTronics, Inc. has secured $66 million in Series B funding round to advance implantable neuromodulation device for treatment-resistant migraine to FDA-approved pivotal clinical trials, the company announced last Wednesday. Co-founded in 2018 by Mudit K. Jain, PhD, CEO and partner at Treo Ventures, ShiraTronics leverages advanced technologies to develop an effective therapy for chronic migraines. The company’s series B round was led by a new investor Norwest Venture Partners, with notable contributions from Seroba., the Global BioAccess Fund, and OSF HealthCare, alongside other undisclosed strategic investors. The round also saw the participation of existing investors Amzak Health, U.S. Venture Partners, Aperture Venture Partners, and Treo Ventures. Read more: https://lnkd.in/gjxksabM #fundingnews #FundingOpportunity #StartupFunding #StartupSuccess #HealthcareNews #MedicalDevice #MigraineTreatment #HealthcareFunding #nextdigitalhealth #Wi4 #vineetagrawal

In the last few days, SamanTree Medical SA, Asceneuron SA, Regenosca SA, DemoSquare and Freesuns have raised several million Swiss Francs 🙌 Despite the uncertain times, Startupticker.ch's latest Swiss Venture Capital Report highlights the region's stability in terms of funding, which these new rounds demonstrate: - SamanTree Medical SA raises $14M to support global expansion and innovation in surgical treatment - Lausanne-based Asceneuron SA raises $100 million for its groundbreaking treatments of neurodegenerative diseases - Regenosca SA closes a CHF 1M pre-seed round for its non-invasive regenerative tissue implants - DemoSquare Closes CHF 1.2 Million Pre-Seed Round - CHF 1 million for Freesuns' solar roof tiles Patrick Barbey points out: "Vaud's innovative fabric continues to show its dynamism during this summer break, with several successive fundraisings, the majority in the life sciences sector. This is due to an ideal setting, with top-class laboratories and a rich academic network, combined with talented entrepreneurs, confirming a trend that has been in place for over ten years." Read more 👉 https://lnkd.in/di2EMDZ9 #VDTech #SwissTech

RECORNEA closes a €150k round!👁️ It's been a while since we've seen rounds in the Italian #medtech sector, but Recornea has closed a €150k funding round led by Roman deep tech fund Scientifica Venture Capital.💸 Founded in 2019 in Trieste and led by CEO Emiliano Lepore, Recornea is a medtech startup that develops ophthalmic therapeutic solutions for corneal diseases, such as keratoconus. Although still in the pre-clinical stage, the startup has developed the proprietary GROSSO implant, the first corneal implant based on nitinol (a nickel-titanium alloy), capable of achieving excellent clinical outcomes in the treatment of the cornea.🧿 Current technologies are not adequate to achieve a total recovery of corneal health from pathologies that deform the shape of the cornea (so-called PCSDs), while GROSSO is able to restore the physiological curvature of the cornea with predictable clinical results that improve the patient's quality of life.👀 Follow Arcadia to discover other Italian startups on the rise!

🔥 Thrilled to share that Simpact Ventures has led a €3M seed round for Ligence, a #Lithuanian medtech startup transforming cardiac diagnostics! Joining us were Coinvest Capital, EIC Fund, Lemonade Stand, NGL Ventures, and Rita Sakus. #Ligence’s AI-powered echocardiography software streamlines image analysis, supporting cardiologists 💊 with precise, guideline-aligned measurements. Unlike typical “black box” tech, their platform integrates smoothly with hospital systems for clearer, actionable insights. With this funding, Ligence aims to make cardiac ultrasound more accessible and accurate, supporting earlier diagnoses, enhanced risk assessments, and better patient screening. This breakthrough also alleviates the manual workload for cardiologists, giving them more time to focus on patient care. ❤️🩹 Kudos to everyone involved! 👏 Read more: https://lnkd.in/dcfphtiS #impactinvesting #medtech #healthcareinnovation #cardiology #investment #digitalhealth

Congrats to Vivalyx, an innovative Organ Vitality Tech startup based in Aachen, on successfully closing an oversubscribed seed funding round, raising above EUR 5 million. Investors include leading European Life Science and Deeptech venture capital firms such as Brightlands Venture Partners, TechVision Fonds, Arve Capital, the American Deeptech VC Goose Capital, and notable private angel investors.   The funding enables Vivalyx to finance the clinical study required for regulatory approval. This crucial step paves the way for the launch of the innovative organ preservation solution, which has the potential to extend the lifespan of donor organs and enhance their vitality. Vivalyx technology aims to significantly increase the number of organs available for transplantation, thus saving and improving the lives of patients worldwide – at significantly lower costs, considerably reduced complexity, and streamlined processes.   Thumbs up also to the international Orrick team including Ilona Schütz, David Hamala, Sven Greulich, Benedikt Migdal and further colleagues.   Orrick, Herrington & Sutcliffe LLP #medtech #lifesciences #organdonation #venturecapital #founders #innovation #TeamOrrick

Investors for Global Digital Therapeutics (DTx) Startups  Through an extensive search and review of publicly available information, 172 startups were selected for detailed analysis regarding their fundraising status. Among these, 94 Digital Therapeutics (DTx) startups have collectively raised $6.859 billion from global investors. These startups include Raft Digital Therapeutics, Mindable Health GmbH, MicroHealth, Vigo Health, SleepUp, Vitadio s.r.o., Neurolief, OPTT Health, Vivira Health, XR Therapeutics, and many others. They are supported by a diverse range of investors, such as aMoon Fund, Expansion Capital, UV-Cap, 7wireVentures, Accelmed Partners, Adage Capital Management, and BCG Digital Ventures, among others. This substantial funding highlights the growing investor confidence and interest in DTx innovations. #dtx #digitaltherapeutics #startup #vc #funding #fundraising #investment

Medeloop Secures $15.5M in Series A Funding to Accelerate Medical Research! We’re delighted to announce that Medeloop has secured $15.5 million in Series A funding, led by Inovia Capital (Magaly Charbonneau), with significant participation from Icon Ventures (Thomas Mawhinney) with the support of General Catalyst (Elena Viboch),  Healthier Capital (Amir Dan Rubin), Maven Ventures (Sara Thomas Deshpande), Up2 Opportunity Fund (Adam Kaufman), and CFO Advisors (Alex Wu). With $25.5M raised to date, Medeloop is scaling efforts to accelerate scientific breakthroughs and bring faster, more impactful solutions to healthcare research. We owe immense gratitude to our dedicated team, expert partners, and valued investors who have believed in our vision. Rene Caissie I Raghav Samavedam I Josh Walonoski I Olushola Adedokun I Daniela Cappa I Alex Bennett I Daniela Amador I Selin C. I Boqian Robert Cheng I Yorick Chern I Lorena Duarte I Anne-Sophie Guernon, M.Sc. I Lauren Green I Allison Hill I Joshua Chan I René Leyva I Hugo Ramirez I Avi Udash, Ashley Moseby I Alex Li I Maya Lockwood I Joshua Hinton I Kaci Madden I Oliver Perez I Germán Pardo #MedicalResearch #ArtificialIntelligence #Healthtech #SeriesA